Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy after induction chemotherapy in patients with indolent non-Hodgkin lymphoma: a single-institution experience

References

• Sarkozy C, Maurer MJ, Link BK, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol. 2019;37(2):144–152. doi:10.1200/JCO.18.00400.
   PubMed Web of Science ®Google Scholar
• Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol. 2009;27(10):1607–1614. doi:10.1200/JCO.2008.17.1561.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51. doi:10.1016/S0140-6736(10)62175-7.
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2011;103(23):1799–1806. doi:10.1093/jnci/djr418.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Radford J, Van Hoof A, et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial. J Clin Oncol. 2013;31(16):1977–1983. doi:10.1200/JCO.2012.45.6400.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90–labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20(10):2453–2463. doi:10.1200/JCO.2002.11.076.
   PubMed Web of Science ®Google Scholar
• Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. 2004;103(12):4429–4431. doi:10.1182/blood-2003-11-3883.
   PubMed Web of Science ®Google Scholar
• Tobinai K, Watanabe T, Ogura M, et al. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci. 2009;100(1):158–164. doi:10.1111/j.1349-7006.2008.00999.x.
   PubMed Web of Science ®Google Scholar
• Spukti EU, Schmidt LH, Schulze A, et al. 90Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): a single-center experience. Eur J Haematol. 2018;101(4):514–521. doi:10.1111/ejh.13138.
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Canales MA, Dlouhy I, et al. A randomized phase II study comparing consolidation with a single dose of 90y ibritumomab tiuxetan (Zevalin®) (Z) vs. maintenance with rituximab (R) for two years in patients with newly diagnosed follicular lymphoma (FL) responding to R-CHOP. preliminary results at 36 months from randomization. Blood. 2013;122(21):369.
   Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068. doi:10.1200/JCO.2013.54.8800.
   PubMed Web of Science ®Google Scholar
• Common terminology criteria for adverse events (CTCAE) version 4.0. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586. doi:10.1200/JCO.2006.09.2403.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481. doi:10.2307/2281868 doi: 10.1080/01621459.1958.10501452
   Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458. doi:10.1038/bmt.2012.244.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26(32):5156–5164. doi:10.1200/JCO.2008.17.2015.
   PubMed Web of Science ®Google Scholar
• Derenzini E, Stefoni V, Maglie R, et al. Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma. Biol Blood Marrow Transplant. 2013;19(12):1695–1701. doi:10.1016/j.bbmt.2013.09.004.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424–435. doi:10.1016/S1470-2045(14)70027-0.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Salles G, Maurer J, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232–2273. doi:10.1007/s12325-017-0612-x.
   PubMed Web of Science ®Google Scholar
• Van Oers MHJ, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853–2858. doi:10.1200/JCO.2009.26.5827.
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular. Blood. 2006;108(13):4003–4008. doi:10.1182/blood-2006-04-016725.
   PubMed Web of Science ®Google Scholar
• Press OW, Unger JM, Rimsza LM, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. 2013;31(20):314–320. doi: 10.1200/JCO.2012.42.4101
   PubMed Web of Science ®Google Scholar
• Burack R, Li H, Spence JM, et al. Subclonal mutations of TP53 are common in untreated follicular lymphoma and mutation status is predictive of PFS when CHOP is combined with 131-iodine tositumomab but not with rituximab: a analysis of SWOG S0016. Blood. 2018;132(suppl 1):919. doi:10.1182/blood-2018-99-111399.
   Web of Science ®Google Scholar
• Press OW, Unger JM, Rimsza LM, et al. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131Iodine-tositumomab. Clin Cancer Res. 2013;19(23):6624–6632. doi:10.1158/1078-0432.CCR-13-1120.
   PubMed Web of Science ®Google Scholar
• Schaefer NG, Huang P, Buchanan JW, et al. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists. J Nucl Med. 2011;52(5):830–838. doi:10.2967/jnumed.110.085589.
   PubMed Web of Science ®Google Scholar
• Barr PM, Li H, Burack WR, et al. R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study. Lancet Haematol. 2018;5:e102–e108. doi:10.1016/S2352-3026(18)30001-2.
   PubMed Web of Science ®Google Scholar
• Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–1344. doi:10.1056/NEJMoa1614598.
   PubMed Web of Science ®Google Scholar